Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin

Hiroki Yoshihara, Yuri Yoshimoto, Yosuke Hosoya, Daisuke Hasegawa, Takafumi Kawano, Akiko Sakoda, Hajime Okita, Atsushi Manabe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Infantile fibrosarcoma is a non-rhabdomyosarcoma soft-tissue sarcoma that occurs in infancy and which has a relatively good prognosis. A vincristine and dactinomycin (VA) regimen has been shown to be effective, although the duration of chemotherapy has not been well defined. We describe the case of a 4-month-old boy with a mass at the left dorsum of the foot who was diagnosed with infantile fibrosarcoma after resection of the tumor, the margin of which was macroscopically positive. VA treatment was carried out with careful monitoring of response and adverse effects. Pancytopenia was seen during the second cycle, and therapy was reduced thereafter. The treatment was continued for 38 weeks (12 cycles). There was no functional impairment, and no evidence of recurrence at 18 months after therapy.

Original languageEnglish
Pages (from-to)371-374
Number of pages4
JournalPediatrics International
Volume59
Issue number3
DOIs
Publication statusPublished - 2017 Mar 1

Fingerprint

Fibrosarcoma
Dactinomycin
Vincristine
Pancytopenia
Therapeutics
Sarcoma
Foot
Recurrence
Drug Therapy
Neoplasms

Keywords

  • adjuvant chemotherapy
  • dactinomycin
  • fibrosarcoma
  • infant
  • vincristine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Yoshihara, H., Yoshimoto, Y., Hosoya, Y., Hasegawa, D., Kawano, T., Sakoda, A., ... Manabe, A. (2017). Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin. Pediatrics International, 59(3), 371-374. https://doi.org/10.1111/ped.13229

Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin. / Yoshihara, Hiroki; Yoshimoto, Yuri; Hosoya, Yosuke; Hasegawa, Daisuke; Kawano, Takafumi; Sakoda, Akiko; Okita, Hajime; Manabe, Atsushi.

In: Pediatrics International, Vol. 59, No. 3, 01.03.2017, p. 371-374.

Research output: Contribution to journalArticle

Yoshihara, H, Yoshimoto, Y, Hosoya, Y, Hasegawa, D, Kawano, T, Sakoda, A, Okita, H & Manabe, A 2017, 'Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin', Pediatrics International, vol. 59, no. 3, pp. 371-374. https://doi.org/10.1111/ped.13229
Yoshihara H, Yoshimoto Y, Hosoya Y, Hasegawa D, Kawano T, Sakoda A et al. Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin. Pediatrics International. 2017 Mar 1;59(3):371-374. https://doi.org/10.1111/ped.13229
Yoshihara, Hiroki ; Yoshimoto, Yuri ; Hosoya, Yosuke ; Hasegawa, Daisuke ; Kawano, Takafumi ; Sakoda, Akiko ; Okita, Hajime ; Manabe, Atsushi. / Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin. In: Pediatrics International. 2017 ; Vol. 59, No. 3. pp. 371-374.
@article{015a9ed40501490f804d93f2a3559890,
title = "Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin",
abstract = "Infantile fibrosarcoma is a non-rhabdomyosarcoma soft-tissue sarcoma that occurs in infancy and which has a relatively good prognosis. A vincristine and dactinomycin (VA) regimen has been shown to be effective, although the duration of chemotherapy has not been well defined. We describe the case of a 4-month-old boy with a mass at the left dorsum of the foot who was diagnosed with infantile fibrosarcoma after resection of the tumor, the margin of which was macroscopically positive. VA treatment was carried out with careful monitoring of response and adverse effects. Pancytopenia was seen during the second cycle, and therapy was reduced thereafter. The treatment was continued for 38 weeks (12 cycles). There was no functional impairment, and no evidence of recurrence at 18 months after therapy.",
keywords = "adjuvant chemotherapy, dactinomycin, fibrosarcoma, infant, vincristine",
author = "Hiroki Yoshihara and Yuri Yoshimoto and Yosuke Hosoya and Daisuke Hasegawa and Takafumi Kawano and Akiko Sakoda and Hajime Okita and Atsushi Manabe",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/ped.13229",
language = "English",
volume = "59",
pages = "371--374",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin

AU - Yoshihara, Hiroki

AU - Yoshimoto, Yuri

AU - Hosoya, Yosuke

AU - Hasegawa, Daisuke

AU - Kawano, Takafumi

AU - Sakoda, Akiko

AU - Okita, Hajime

AU - Manabe, Atsushi

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Infantile fibrosarcoma is a non-rhabdomyosarcoma soft-tissue sarcoma that occurs in infancy and which has a relatively good prognosis. A vincristine and dactinomycin (VA) regimen has been shown to be effective, although the duration of chemotherapy has not been well defined. We describe the case of a 4-month-old boy with a mass at the left dorsum of the foot who was diagnosed with infantile fibrosarcoma after resection of the tumor, the margin of which was macroscopically positive. VA treatment was carried out with careful monitoring of response and adverse effects. Pancytopenia was seen during the second cycle, and therapy was reduced thereafter. The treatment was continued for 38 weeks (12 cycles). There was no functional impairment, and no evidence of recurrence at 18 months after therapy.

AB - Infantile fibrosarcoma is a non-rhabdomyosarcoma soft-tissue sarcoma that occurs in infancy and which has a relatively good prognosis. A vincristine and dactinomycin (VA) regimen has been shown to be effective, although the duration of chemotherapy has not been well defined. We describe the case of a 4-month-old boy with a mass at the left dorsum of the foot who was diagnosed with infantile fibrosarcoma after resection of the tumor, the margin of which was macroscopically positive. VA treatment was carried out with careful monitoring of response and adverse effects. Pancytopenia was seen during the second cycle, and therapy was reduced thereafter. The treatment was continued for 38 weeks (12 cycles). There was no functional impairment, and no evidence of recurrence at 18 months after therapy.

KW - adjuvant chemotherapy

KW - dactinomycin

KW - fibrosarcoma

KW - infant

KW - vincristine

UR - http://www.scopus.com/inward/record.url?scp=85015767635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015767635&partnerID=8YFLogxK

U2 - 10.1111/ped.13229

DO - 10.1111/ped.13229

M3 - Article

VL - 59

SP - 371

EP - 374

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 3

ER -